Haematologische Onkologische Praxis im Medicum
- Address
- Schwachhauser Strasse 50, 28209 Bremen, Germany
Neoplasm Clinical Research
The Haematologische Onkologische Praxis im Medicum focuses on neoplasms, primarily studying HR+/HER2- negative breast cancer in both early and metastatic stages.
- Long‑term disease stabilization after stopping CDK4/6 inhibitors combined with continued endocrine therapy.
- Comparison of ribociclib plus endocrine therapy versus standard chemotherapy to improve invasive disease‑free survival.
This work supports the development of more durable treatment strategies for patients in Bremen and beyond.
HR+/HER2- Negative Breast Cancer Trials
Clinical investigations target HR+/HER2- negative early breast cancer and its metastatic counterpart, aiming to refine therapeutic choices.
- Assessment of disease control when CDK4/6 inhibitors are discontinued after at least 12 months of stable response.
- Evaluation of a dynamic marker‑guided approach using ribociclib in intermediate‑risk early disease.
Results aim to personalize care and extend survival for patients with hormone‑responsive disease.
Targeted Endocrine Therapy Development
The site evaluates novel combinations of endocrine therapy with targeted agents to boost outcomes in hormone‑responsive cancers.
- Investigating the superiority of ribociclib plus endocrine therapy on 5‑year distant disease‑free survival.
- Monitoring quality of life during low‑intervention trials of CDK4/6 inhibitor discontinuation.
By integrating biomarkers and patient‑reported outcomes, the practice seeks to set new standards for quality of life and long‑term survival.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Haematologische Onkologische Praxis im Medicum
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ribociclib | 2 | Unknown | 2019-07-02 | 2024-01-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.